Association of S100B polymorphisms and serum S100B with risk of ischemic stroke in a Chinese population

Yu-Lan Lu\(^1\), Rong Wang\(^2\), Hua-Tuo Huang\(^1\), Hai-Mei Qin\(^1\), Chun-Hong Liu\(^1\), Yang Xiang\(^1\), Chun-Fang Wang\(^1\), Hong-Cheng Luo\(^1\), Jun-Li Wang\(^1\), Yan Lan\(^2\) & Ye-Sheng Wei\(^1\)

The levels of serum S100B were elevated in patients with ischemic stroke (IS), which may be a novel biomarker for diagnosing IS. The aim of this study was to investigate the association of S100B polymorphisms and serum S100B with IS risk. We genotyped the S100B polymorphisms rs9722, rs984765, rs2839356, rs1051169 and rs2186358 in 396 IS patients and 398 controls using polymerase chain reaction-single base extension (SBE-PCR). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). Rs9722 was associated with an increased risk of IS (AA vs. GG: adjusted OR = 2.172, 95% CI, 1.175–4.014, P = 0.013; dominant: adjusted OR = 1.507, 95% CI, 1.071–2.123, P = 0.019; recessive: adjusted OR = 1.846, 95% CI, 1.025–3.323, P = 0.041; additive: adjusted OR=1.371, 95% CI, 1.109-1.694, P = 0.003). The A-C-C-C-A haplotype was associated with an increased risk of IS (OR = 1.325, 95% CI, 1.035–1.696, P = 0.025). In addition, individuals carrying the rs9722 GA/AA genotypes had a higher serum S100B compared with the rs9722 GG genotype in IS patients (P = 0.018).

Our results suggest that the S100B gene rs9722 polymorphism may contribute to the susceptibility of IS, probably by promoting the expression of serum S100B.

Stroke is a multi-factorial disease that constitutes one of the leading causes of adult disability worldwide\(^1\)-\(^3\). In recent years, the incidence of stroke has increased dramatically in China\(^4\). Approximately 80% of strokes are ischemic in origin. Ischemic stroke (IS) is the result of interrupted blood flow within the area of an occluded blood vessel, causing local brain tissue to become deprived of oxygen, ending in malacia and necrosis. Several risk factors have been identified to contribute to the pathogenesis of IS, including age, gender, obesity, hypertension, diabetes, smoking and dyslipidaemia\(^5\). However, these conventional risk factors do not fully account for the overall risk of IS. Several lines of evidence have indicated that genetic factors are also involved in the development of IS\(^6,7\). To date, the possible relationship of IS with altered transcription of genes has not been ruled out.

S100 calcium-binding protein B (S100B) belongs to the large superfamily of S100, which is mainly expressed by astrocytes in the brain and plays a crucial role in cell proliferation, differentiation, apoptosis, signal transduction, cellular energy and metabolism\(^8,9\). Furthermore, by interacting with the receptor for advanced glycation end products (RAGE), S100B can activate microglial cells and stimulate the secretion of inflammatory cytokines, such as tumour necrosis factor-\(\alpha\) (TNF-\(\alpha\)), interleukin-\(1\beta\) (IL-1\(\beta\)) and the chemokine 22 (CCL22), and upregulate the expression of the proinflammatory enzyme COX-2\(^10,11\). These cytokines have been previously reported to play a role in the pathogenesis of IS\(^12-16\). More recently, increasing evidence has identified that serum S100B levels may be used as a potential biomarker for cardiovascular diseases\(^17-22\). In addition, evidence from clinical studies and animal models have suggested that elevated levels of serum S100B play a vital role in the development of IS\(^23-28\). Taken together, these findings indicate that S100B may represent a promising candidate for the treatment of IS.

Single nucleotide polymorphisms (SNPs) are the most common variants in human genomes and have been used frequently as genetic markers in genome-wide association studies (GWAS)\(^29\). The human S100B gene is

\(^1\)Department of Clinical Laboratory, Affiliated Hospital of Youjiang Medical University for Nationalities, No.18 Zhongshan Road II, Baise, 533000, Guangxi, China. \(^2\)Department of Dermatology, Affiliated Hospital of Youjiang Medical University for Nationalities, No.18 Zhongshan Road II, Baise, 533000, Guangxi, China. Yu-Lan Lu and Rong Wang contributed equally to this work. Correspondence and requests for materials should be addressed to Y.-S.W. (email: yeshengwei22@163.com)
located on chromosome 21q22.3, which consists of 3 exons and 2 introns. Previously, a number of studies have indicated that S100B polymorphisms may modulate an individual’s susceptibility to several human diseases, such as schizophrenia, dyslexia, autism and bipolar affective disorder. However, to our knowledge, no study has investigated the associations between S100B polymorphisms and IS susceptibility. Therefore, the aim of this study was to investigate the association of the five SNPs in the S100B gene with susceptibility to IS in a Chinese population. Moreover, the effect of S100B polymorphisms on the levels of serum S100B was also assessed.

### Results

#### Clinical characteristics of the study participants.

The clinical characteristics of IS patients and controls are summarized in Table 1. There were no significant differences between the two groups based on age, gender and TCH (P > 0.05). The frequencies of hypertension, diabetes mellitus and smoker in IS patients were significantly higher than those in controls (P < 0.05). Increased levels of TG, LDL-C, VLDL-C and lower levels of HDL-C were observed in IS patients compared with controls (P < 0.001).

#### Association of S100B polymorphisms with IS risk.

All five SNP genotypes were in HWE among control subjects (P > 0.05). The association between S100B polymorphisms and risk of IS under genotype and genetics models analysis are shown in Table 2. We observed that the rs9722 AA genotype was associated with an increased risk of IS compared with the GG genotype, even after adjusting for age, gender, hypertension, diabetes mellitus and smoker in IS patients were controls (AA vs. GG: adjusted OR = 1.175, 95% CI, 1.075–4.014, P = 0.013). Similarly, a significantly increased risk was also observed in the dominant model (GA vs. GG: adjusted OR = 1.507, 95% CI, 1.071–2.123, P = 0.019), recessive model (AA vs. GA/GG: adjusted OR = 1.846, 95% CI, 1.025–3.232, P = 0.041) and additive model (A vs. G: adjusted OR=1.371, 95% CI, 1.109-1.694, P = 0.003). However, after correction for multiple comparisons, all associations described above lost statistical significance. Studies with greater sample sizes are needed to confirm these associations.

#### Distribution of the S100B gene rs9722 polymorphism in different populations.

Because rs9722 may play an important role in the development of IS, we then performed a comparison of the genotype distribution of rs9722 in different populations (Table 3). The results showed that the genotype distribution of rs9722 in our study was significantly different compared with HM-HCB, HM-JPT, HM-CEU, HM-YRI, HM-ASW, HM-LWK, HM-MEX, HM-MKK and HM-TSI (P < 0.05). However, no significant difference was found when comparing with HM-CHB, HM-CHD and HM-GH1 (P > 0.05).

#### Haplotype analysis of the S100B gene.

Haplotype analysis was performed and the possible five haplotype frequencies are shown in Table 4. The results showed that rs9984765 was in strong linkage disequilibrium (LD) with rs2839356 (D’=0.931) and rs1051169 (D’=0.882). Similarly, rs2839356 was in strong LD with rs1051169 (D’=0.852) and rs2186358 (D’=0.805). Moreover, we found that the A-C-C-A-C haplotype was associated with an increased risk of IS (OR = 1.325, 95% CI, 1.035–1.696, P = 0.025). The G-T-T-C-C haplotype was associated with a decreased risk of IS (OR = 0.480, 95% CI, 0.275–0.838, P = 0.008).

#### Association of S100B polymorphism and serum S100B levels.

We then investigated the association between S100B polymorphisms and serum S100B levels. As shown in Fig. 1, the levels of serum S100B were significantly up-regulated in IS patients compared with controls [(115.03 ± 44.42) pg/mL vs. (70.53 ± 30.98) pg/mL, P < 0.001]. Notably, we found that patients carrying the rs9722 GA/AA genotypes had a higher expression of serum S100B compared with those carrying the rs9722 GG genotype [(123.98 ± 47.42) pg/mL vs. (101.33 ± 36.98) pg/mL, P = 0.018].

#### Discussion

To our knowledge, this is the first report to determine whether S100B polymorphisms and the levels of serum S100B are associated with IS in the Chinese population. In this study, we observed that the rs9722 AA genotype, dominant model, recessive model and additive model were associated with significantly increased risk of IS. An

| Variables                  | Controls (n = 398) | IS patients (n = 396) | P value |
|----------------------------|-------------------|----------------------|---------|
| Age, years (mean ± SD)     | 58.09 ± 8.76      | 59.16 ± 9.18         | 0.093   |
| Gender (M/F)               | 231/167           | 252/144              | 0.106   |
| Hypertension, n (%)        | 88 (22.1%)        | 161 (40.6%)          | <0.001  |
| Diabetes mellitus, n (%)   | 41 (10.3%)        | 64 (16.2%)           | 0.015   |
| Smoker, n (%)              | 62 (15.6%)        | 116 (29.3%)          | <0.001  |
| TCH, mmol/L                | 4.84 ± 0.74       | 4.78 ± 1.23          | 0.390   |
| TG, mmol/L                 | 1.24 ± 0.74       | 1.60 ± 1.09          | <0.001  |
| HDL-C, mmol/L              | 1.66 ± 0.39       | 1.26 ± 0.35          | <0.001  |
| LDL-C, mmol/L              | 2.47 ± 0.56       | 2.64 ± 0.89          | <0.001  |
| VLDL-C, mmol/L             | 0.57 ± 0.36       | 0.73 ± 0.49          | <0.001  |

Table 1. Clinical characteristics of the study population. IS, ischemic stroke; SD, standard deviation; M, male; F, female; TCH, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; VLDL-C, very low density lipoprotein-cholesterol.
increased risk was also observed in the haplotype analysis. Moreover, we found that the levels of serum S100B were significantly up-regulated in IS patients compared with controls. Interestingly, the rs9722 GA/AA genotypes corresponded to higher levels of serum S100B. The statistical power of the study was calculated to be 91% to detect the association between rs9722 polymorphism and IS risk in a sample size of 794 participants (396 IS patients and 398 controls), assuming an OR of 1.6 and \( \alpha \) of 0.05 (PASS 15.0 software). Therefore, these findings indicate that the \( S100B \) gene rs9722 polymorphism may serve as a novel genetic marker of susceptibility to IS in the Chinese population.

**Table 2.** Association between the \( S100B \) polymorphisms and risk of IS. IS, ischemic stroke; OR, odds ratio; 95% CI, 95% confidence interval. \(^\dagger\) Adjusted by age, gender, hypertension, diabetes mellitus, smoker, TCH, TG, HDL-C, LDL-C and VLDL-C. \( P_{BH} \): \( P \) values corrected by Benjamin-Hochberg (B-H) method.

| SNPs  | Controls (n = 398) | IS patients (n = 396) | AOR (95% CI) \(^\dagger\) | \( P \) | \( P_{BH} \) |
|-------|------------------|----------------------|--------------------------|------|--------|
|       | GG               | GA                   | AA                       | Dominant | Recessive | Additive |
| rs9722| 197 (49.5)       | 163 (41.2)           | 1,000 (ref)              |       |         |         |
|       | 175 (44.0)       | 186 (47.0)           | 1.392 (0.973–1.993)      | 0.071 | 0.213  |         |
|       | 26 (6.5)         | 47 (11.9)            | 2.172 (1.175–4.014)      | 0.013 | 0.095  |         |
|       | 1.507 (1.071–2.123) |         | 0.019 | 0.095  |         |
|       | 1.846 (1.025–3.323) |         | 0.041 | 0.154  |         |
|       | 1.371 (1.109–1.694) |         | 0.003 | 0.045  |         |
|       | TT               | CT                   | CC                       | Dominant | Recessive | Additive |
| rs9984765| 190 (47.7)       | 176 (44.4)           | 1.000 (ref)              |       |         |         |
|       | 177 (44.5)       | 179 (45.2)           | 1.290 (0.902–1.845)      | 0.163 | 0.348  |         |
|       | 31 (7.8)         | 41 (10.4)            | 1.497 (0.817–2.743)      | 0.192 | 0.348  |         |
|       | 1.325 (0.941–1.864) |         | 0.107 | 0.268  |         |
|       | 1.320 (0.740–2.354) |         | 0.347 | 0.377  |         |
|       | 1.146 (0.927–1.416) |         | 0.289 | 0.348  |         |
|       | TT               | CT                   | CC                       | Dominant | Recessive | Additive |
| rs28393356| 196 (49.2)       | 182 (46.0)           | 1.000 (ref)              |       |         |         |
|       | 174 (43.7)       | 178 (44.9)           | 1.194 (0.837–1.703)      | 0.327 | 0.377  |         |
|       | 28 (7.1)         | 36 (9.1)             | 1.080 (0.574–2.032)      | 0.812 | 0.508  |         |
|       | 1.175 (0.837–1.650) |         | 0.352 | 0.377  |         |
|       | 0.992 (0.539–1.824) |         | 0.979 | 0.587  |         |
|       | 1.115 (0.900–1.382) |         | 0.320 | 0.377  |         |
|       | TT               | CT                   | CC                       | Dominant | Recessive | Additive |
| rs1051169| 164 (41.2)       | 153 (38.6)           | 1.000 (ref)              |       |         |         |
|       | 178 (44.7)       | 186 (47.0)           | 1.149 (0.795–1.660)      | 0.460 | 0.406  |         |
|       | 56 (14.1)        | 57 (14.4)            | 1.152 (0.684–1.942)      | 0.595 | 0.406  |         |
|       | 1.150 (0.812–1.627) |         | 0.432 | 0.406  |         |
|       | 1.069 (0.660–1.731) |         | 0.787 | 0.508  |         |
|       | 1.064 (0.868–1.304) |         | 0.551 | 0.406  |         |
|       | AA               | AC                   | CC                       | Dominant | Recessive | Additive |
| rs2186358| 328 (82.4)       | 336 (84.8)           | 1.000 (ref)              |       |         |         |
|       | 63 (15.8)        | 56 (14.2)            | 0.876 (0.549–1.398)      | 0.579 | 0.406  |         |
|       | 7 (1.8)          | 4 (1.0)              | 0.608 (0.130–2.857)      | 0.529 | 0.406  |         |
|       | 0.853 (0.543–1.340) |         | 0.490 | 0.406  |         |
|       | 0.621 (0.132–2.910) |         | 0.545 | 0.406  |         |
|       | 0.821 (0.580–1.162) |         | 0.265 | 0.377  |         |

Stroke is one of the major causes of death and long-term disability worldwide. Globally, there are >50 million stroke patients, producing an immense burden on the economic and healthcare infrastructure. To date, however, the exact aetiology and pathogenetic mechanisms of IS remain unclear. Recently, increasing evidence has indicated that serum S100B levels may be used as a novel biomarker for IS. Nevertheless, the mechanisms leading to elevated serum S100B are unknown, but this is believed to lead to aggravation of the development of IS. In the present study, our results also showed that the levels of serum S100B in IS patients were significantly higher than in controls. The results of our study suggest that S100B may play a crucial role in the aetiology of IS.

Recently, several studies have been conducted to investigate the effect of the rs9722 polymorphism on human diseases. Matsson et al. reported that the rs9722 polymorphism was associated with dyslexia, and the T allele was suggested as a risk factor for the development of dyslexia. Hohoff et al. found that the rs9722 AA genotype was significantly associated with the high expression of S100B in the prefrontal cortex or peripheral blood. Li et al. demonstrated that the rs9722 T allele was associated with the risk of severe hand, foot and mouth disease. Similarly, a case-control study conducted by Liu et al. reported that the rs1051169-rs9722 (G-C) haplotype may
have a possible susceptibility to increase the expression of serum S100B. In contrast, Yang et al. showed that the rs9722 polymorphism was not correlated with the risk of major depressive disorder in a Chinese population. To date, no association study has been reported on the association between the rs9722 polymorphism and IS. However, in this study, we found that the rs9722 AA genotype, dominant, recessive and additive model display an increased risk of IS. Additionally, the levels of serum S100B were found to be elevated in IS patients. Interestingly, we observed that the individuals carrying the rs9722 GA/AA genotypes had a higher serum S100B compared with the rs9722 GG genotype in IS patients. In summary, these results suggest that the S100B gene rs9722 polymorphism may be responsible for susceptibility to IS, probably through up-regulation of the expression of serum S100B.

Until now, very limited data have been reported on the association of rs9984765, rs2839356 and rs2186358 polymorphisms with disease susceptibility. A previous study conducted by Hohoff et al. reported that the T-G-A (rs2186358-rs11542311-rs2300403-rs9722) haplotype was associated with elevated levels of serum S100B. Meanwhile, the G-A-T-C (rs11542311-rs2839356-rs9984765-rs881827) haplotype was associated with increased expression of S100B mRNA in postmortem frontal cortices. Regarding the rs1051169 polymorphism, Guo et al. have tried to detect the association of the rs1051169 polymorphism with Parkinson’s disease in a Chinese population, but failed to find a positive result. However, Liu et al. found that the rs1051169 polymorphism was associated with an increased risk of schizophrenia in the Chinese population.

In the present study, we failed to find any association of the rs9984765, rs2839356, rs1051169 and rs2186358 polymorphisms with IS risk. Two possibilities should be taken into account to explain the negative results. First, it may be because of genetic trait differences, as we know that genetic polymorphisms in human genes are distinct in specific populations, various ethnicities and geographic regions. Data from Table 3 support this viewpoint, we observed that the genotype distribution of rs9722 in our study showed significant differences compared with the HM-HCB, HM-JPT, HM-CEU, HM-YRI, HM-LWK, HM-MEX, HM-MKK and HM-TSI populations, but was similar to the HM-CHB, HM-CHD and HM-GIH populations. Secondly, stroke is a multi-factorial disease that is regulated by genetic and environmental factors; thus, individual exposure to different environmental factors and genetic susceptibility might have caused different results.

S100B, produced mainly by activated astrocytes, has already been confirmed to participate in regulating cell proliferation, differentiation and apoptosis. Previous studies have identified that extracellular S100B binds to its membrane receptor RAGE and then activates a series of cellular signalling pathways and leads to the production of TNF-α, IL-1β, IL-6 and VCAM-1. Serum levels of IL-1β and IL-6 were significantly increased in IS.

### Table 3. Distribution of the rs9722 polymorphism in different populations. *P* < 0.05 comparing with our present data; HM: Haplotype Map; CHB: Han Chinese in Beijing, China; HCB: Han Chinese in Beijing, China; CHD: Chinese in Metropolitan Denver, Colorado; JPT: Japanese in Tokyo, Japan; CEU: Utah residents with northern and western European ancestry; YRI: Yoruba in Ibadan, Nigeria; ASW: African ancestry in Southwest USA; GIH: Gujarati Indians in Houston, Texas; LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai in Kinyawa, Kenya; TSI: Toscan in Italy.

| Group     | N   | Genotype (%) | Allele (%) | Ethnicity |
|-----------|-----|--------------|------------|-----------|
| Our data  | 398 | GG 197 (49.5) GA 175 (44.0) AA 26 (6.5) | G 569 (71.5) A 227 (28.5) | Guangxi  |
| HM-CHB    | 82  | 46 (56.1) GA 26 (31.7) AA 10 (12.2) | A 118 (72.0) G 46 (28.0) | Asian    |
| HM-HCB    | 84  | 26 (30.9) GA 44 (52.4) AA 14 (16.7) | A 96 (57.1) G 72 (42.9) | Asian    |
| HM-CHD    | 170 | 82 (48.2) GA 78 (45.9) AA 10 (5.9) | A 242 (71.2) G 98 (28.8) | Asian    |
| HM-JPT    | 172 | 60 (34.9) GA 98 (57.0) AA 14 (8.1) | A 218 (63.4) G 126 (36.6) | Asian    |
| HM-CEU    | 226 | 184 (81.4) GA 40 (17.7) AA 2 (0.9) | A 408 (90.3) G 44 (9.7) | European |
| HM-YRI    | 226 | 26 (40.3) GA 124 (54.9) AA 6 (24.8) | A 216 (47.8) G 236 (52.2) | African  |
| HM-ASW    | 98  | 36 (37.6) GA 50 (51.0) AA 12 (12.3) | A 122 (62.2) G 74 (37.8) | African  |
| HM-GIH    | 174 | 90 (51.7) GA 72 (41.4) AA 12 (6.9) | A 252 (72.4) G 96 (27.6) | Asian    |
| HM-LWK    | 176 | 64 (36.4) GA 82 (46.6) AA 30 (17.0) | A 210 (59.7) G 142 (40.3) | Asian    |
| HM-MEX    | 100 | 78 (78.0) GA 22 (22.0) — AA 178 (89.0) | A 22 (11.0) | America  |
| HM-MKK    | 284 | 78 (27.5) GA 144 (50.7) AA 62 (21.8) | A 300 (52.8) G 268 (47.2) | African  |
| HM-TSI    | 176 | 154 (87.5) GA 20 (11.4) AA 2 (1.1) | A 328 (93.2) G 24 (6.8) | European |

### Table 4. Haplotype analysis of the S100B polymorphisms with risk of IS. IS, ischemic stroke; OR, odds ratio; 95% CI, 95% confidence interval.

| Haplotype | Controls (2n = 792) | IS patients (2n = 792) | OR (95% CI) | P value |
|-----------|---------------------|-----------------------|-------------|---------|
| G T T G A  | 414 (52.0)          | 385 (48.6)            | 0.899 (0.726–1.113) | 0.329 |
| A C C C A  | 152 (19.1)          | 183 (23.1)            | 1.325 (1.035-1.696) | 0.025 |
| G C C C A  | 47 (5.9)            | 41 (5.2)              | 0.891 (0.579–1.372) | 0.600 |
| A T T G A  | 46 (5.7)            | 51 (6.5)              | 1.163 (0.769–1.760) | 0.474 |
| G T T C C  | 40 (5.0)            | 19 (2.4)              | 0.480 (0.275–0.838) | 0.008 |

 SCIENCl. REPORTS | (2018) 8:971 | DOI:10.1038/s41598-018-19156-w
DNA Extraction and Genotyping. Blood samples from all subjects were collected in EDTA-containing tubes. Genomic DNA was isolated from peripheral blood mononuclear cells using a DNA extraction kit (QIANGEN, China) according to the manufacturer’s instructions and then stored at −70 °C for later use. Primer probes were designed using Primer Express Software (version 3.0) and synthesized and supplied by Applied Biosystems (United States). Primer sequences are presented in Table 5. Genotyping was performed using SBE-PCR. The PCRs were performed in a total volume of 20 μL containing 3.0 mmol/L MgCl₂, 0.3 mmol/L dNTPs, 1 U HotStarTaq polymerase (QIANGEN, China), 1 μL genomic DNA, 1 μL PCR primer and 1 × GC-I buffer (Takara). The PCR conditions included an initial denaturation step at 94 °C for 20 s, followed by 35 cycles with 20 s of denaturation at 94 °C, 30 s of annealing at 59 °C and 1.5 min of elongation at 72 °C, followed by a final elongation step of 72 °C for 2 min. PCR products were digested with Shrimp enzyme (SAP, from Promega) and excision enzyme (EXO I, from Epicentre). An ABI PRISM 3730XL analyser (PE Applied Biosystems, Foster City,
10. Bianchi, R., Giambanco, I. & Donato, R. S100B/RAGE-dependent activation of microglia via NF-kappaB and AP-1 Co-regulation

9. Yamaguchi, F.

7. Munshi, A., Das, S. & Kaul, S. Genetic determinants in ischaemic stroke subtypes: seven year findings and a review.

5. An, S. J., Kim, T. J. & Yoon, B. W. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update.

4. Gao, F., Sun, R. J., Ji, Y. & Yang, B. F. Cardiovascular research is thriving in China.

3. Barker-Collo, S.

2. Barker-Collo, S. et al. Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology 43, 203–214, https://doi.org/10.1159/000441103 (2015).

1. Nicholson, G., Gandra, S. R., Halbert, R. J., Richhariya, A. & Nordyke, R. J. Patient-level costs of major cardiovascular conditions: a review of the international literature. ClinicoEconomics and outcomes research 8, 495–506, https://doi.org/10.2147/ceor.s89331 (2016).

CA, USA) sequenced the PCR products. The samples were reanalysed and verified by DNA sequencing if conflict results occurred. In addition, approximately 10% of all samples were randomly selected to be confirmed by DNA sequencing, and the results were 100% consistent.

Serum S100B determination. Serum samples from IS patients and control subjects were separated from peripheral venous blood at room temperature and stored at −70 °C until use. The quantity determination of the levels of serum S100B was performed by ELISA kits (Human S100B, BioVendor, No: RD192090100R) following the manufacturer’s protocol. The developed colour reaction was measured as OD450 units on an ELISA reader (RT-6000, China). The concentration of serum S100B was determined using a standard curve constructed with the kit’s standards over the range of 10–320 pg/mL.

Statistical analysis. All data were analysed with the software Statistical Package for Social Science (SPSS) for Windows, version 17.0 (SPSS, Inc., Chicago, USA). Hardy-Weinberg equilibrium (HWE) was tested by the chi-square test. Categorical variables were expressed as proportions and compared using the chi-squared test. Continuous variables were displayed the as mean ± SD. If the data were normally distributed, Student’s t-test was used; otherwise, the Mann-Whitney U test was used. The odds ratio (OR) and 95% confidence intervals (CI) were calculated to provide a measure of the strength of the S100B polymorphisms on IS risk. Logistic regression analysis was performed to estimate the putative association between the SNPs and the risk of IS while adjusting for age, sex, hypertension, diabetes, smoker, TCH, TG, HDL-L, LDL-L and VLDL-L. We carried out multiple hypothesis testing using the Benjamini-Hochberg method to control the false discovery rate (FDR) in the unconditional logistic regression analysis. Haplotype analysis was performed on an online tool SHEsis50. Statistical significance was set at P < 0.05.

References

1. Nicholson, G., Gandra, S. R., Halbert, R. J., Richhariya, A. & Nordyke, R. J. Patient-level costs of major cardiovascular conditions: a review of the international literature. ClinicoEconomics and outcomes research 8, 495–506, https://doi.org/10.2147/ceor.s89331 (2016).

2. Barker-Collo, S. et al. Sex Differences in Stroke Incidence, Prevalence, Mortality and Disability-Adjusted Life Years: Results from the Global Burden of Disease Study 2013. Neuroepidemiology 43, 203–214, https://doi.org/10.1159/000441103 (2015).

3. Goljar, N., Burger, H., Videnov, G., Leonard, M. & Marincek, C. Measuring patterns of disability using the International Classification of Functioning, Disability and Health in the post-acute stroke rehabilitation setting. Journal of rehabilitation medicine 43, 590–601, https://doi.org/10.2340/16501977-0832 (2011).
46. Cao, T. et al. S100B promotes injury-induced vascular remodeling through modulating smooth muscle phenotype. *Biochimica et biophysica acta* [https://doi.org/10.1016/j.bbadis.2017.07.002](https://doi.org/10.1016/j.bbadis.2017.07.002) (2017).

47. Beer, C., Blacker, D., Bynevelt, M., Hankey, G. J. & Puddey, I. B. Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. *Journal of neuroinflammation* 7, 71, [https://doi.org/10.1186/s12974-010-0007-0](https://doi.org/10.1186/s12974-010-0007-0) (2010).

48. Mori, T. et al. Overexpression of human S100B exacerbates brain damage and perifocal gliosis after permanent focal ischemia. *Stroke: a journal of cerebral circulation* 39, 2114–2121, [https://doi.org/10.1161/STROKEAHA.107.503821](https://doi.org/10.1161/STROKEAHA.107.503821) (2008).

49. Tokuno, S. et al. Spontaneous ischemic events in the brain and heart adapt the hearts of severely atherosclerotic mice to ischemia. *Arteriosclerosis, thrombosis, and vascular biology* 22, 995–1001 (2002).

50. Shi, Y. Y. & He, L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. *Cell research* 15, 97–98, [https://doi.org/10.1038/sj.cr.7290272](https://doi.org/10.1038/sj.cr.7290272) (2005).

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (No. 81560552; No. 81260234) and the Innovation project of Guangxi Graduate Education (NO. YCSW2017213).

**Author Contributions**

Yu-Lan Lu and Rong Wang designed and wrote the manuscript. Hua-Tuo Huang, Chun-Hong Liu and Hai-Mei Qin performed experiments. Chun-Fang Wang and Jun-Li Wang collected samples. Hong-Cheng Luo and Yang Xiang performed the statistical analysis and prepared the figure. Yan Lan and Ye-Sheng Wei conceived and designed the experiments. All authors read and approved the manuscript.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2018